Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ:BCYC) reported Q3 2020 financial results, highlighting advancements in its clinical pipeline despite COVID-19 challenges. Notable developments include the initiation of Phase IIa trials for BT1718 and BT8009, and a $50 million capital raise through an At-the-Market (ATM) offering. The company holds $149.8 million in cash as of September 30, 2020, up from $92.1 million at year-end 2019. However, it recorded a net loss of $10.1 million, slightly increasing from $9.5 million year-over-year. The company continues to expand its Scientific Advisory Board, enhancing its research capabilities.
Bicycle Therapeutics (NASDAQ: BCYC) announced the appointment of four prominent scientists to its Scientific Advisory Board, enhancing its capabilities in oncology and immunology. The new members include Drs. Garret FitzGerald, Jane Grogan, Caetano Reis e Sousa, and Charles Swanton. Their expertise is expected to guide the development of Bicycle’s innovative Bicycle-based therapeutics, which aim to establish new treatment paradigms for cancer. The company is currently advancing multiple clinical trials, including BT1718 and BT5528, targeting significant tumor antigens.
Summary not available.
Bicycle Therapeutics (NASDAQ: BCYC) has successfully completed its at-the-market (ATM) offering, raising gross proceeds of $50 million. Additionally, the company secured a $40 million term loan from Hercules Capital, with $30 million available at closing. These financings enhance Bicycle's financial stability as it progresses multiple clinical programs, including its lead candidate BT7480, slated for initiation next year. The company aims to achieve key clinical milestones in 2021, leveraging approximately $120 million raised in 2020, over half of which was non-dilutive.